Rigor Reviewed

Rigor-Reviewed Manuscript

Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype.

Name: Αlpha¹ Rigor Record — Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype.
Item: Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype.
Rating: 96
Author: Αlpha¹

Jackson DJ, Wechsler ME, Jackson DJ, Bernstein D, Korn S, Pfeffer PE, Chen R, Saito J, de Luíz Martinez G, Dymek L, Jacques L, Bird N, Schalkwijk S, Smith D, Howarth P, Pavord ID, SWIFT-1 and SWIFT-2 Investigators, SWIFT-1 Investigators, SWIFT-2 Investigators

Paper source

Read full text

Embed this Rigor badge

Αlpha¹ Rigor Review — 4.75★ (Strong), 0 critical, 2 high issues for “Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

4.75 / 5

Strong — minor issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 32 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.
Declared data/code links were not checked for liveness or content.

Problems surfaced1 type

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper reports two well-designed, rigorously conducted phase 3 trials with clear scientific rationale, detailed methods, and transparent reporting. The main weakness is the vague data availability statement and minor reporting gaps (statistical software, informed consent, reporting guideline).

Both reviewers classified the study as interventional, and I adopted that. The evaluation covered all eight dimensions; species/strain/housing and cell line sub-criteria were not applicable for this human trial. The statistics verification checked only 4 tests (all consistent); other reported statistics were not machine-verified.

4 major claims checked against the paper's own evidence: all adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Recomputed 4 tests: 4 consistent, 0 inconsistent; 4 via agent-written checks.

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites multiple prior studies (references 1-19) establishing the role of IL-5 in eosinophilic asthma, the efficacy of shorter-acting anti-IL-5 biologics, and the phase 1 data for depemokimab. The rationale linking the need for less frequent dosing to improved patient quality of life is logically presented. Limitations of prior therapies (dosing frequency) are acknowledged and addressed by the study design.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with extensive prior work and a logical rationale for the study.

Evidence

paraphrase[Introduction, paragraph 1-3]

“In 2009, proof-of-concept trials showed that the anti–interleukin-5 antibody mepolizumab reduced the frequency of exacerbations in patients who had a sputum eosinophil count of more than 3% and a history of exacerbations.”

paraphrase[Introduction, paragraph 4]

“Depemokimab is an ultra-long-acting biologic therapy with enhanced binding affinity for interleukin-5, which potentially enables effective 6-month dosing intervals for patients with asthma.”

absence[Introduction]

Limitations of prior work are not explicitly discussed as such.

PASSReviewer 2· 95% conf

The paper clearly establishes the scientific premise by citing prior work on interleukin-5 biology, anti-IL-5 therapies, and the rationale for depemokimab's ultra-long-acting design.

Evidence

paraphrase[Introduction, paragraphs 1-3]

“Interleukin-5 is responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils... In 2009, proof-of-concept trials showed that the anti–interleukin-5 antibody mepolizumab reduced the frequency of exacerbations...”

paraphrase[Introduction, paragraph 4]

“Depemokimab is an ultra-long-acting biologic therapy with enhanced binding affinity for interleukin-5, which potentially enables effective 6-month dosing intervals for patients with asthma.”

paraphrase[Discussion, paragraph 3]

“Our findings regarding depemokimab represent a potential advance in patient quality of life because therapies that have a reduced dosing frequency are associated with a lower patient-reported treatment burden...”

Randomization method (RandAll NG, block size six, stratified by ICS dose) and unit (patient) are reported. Blinding is described (trial staff, patients, investigators unaware). Power analysis is referenced but details are in the supplementary appendix. Inclusion/exclusion criteria are detailed. Outlier handling is addressed via the full analysis population definition and exclusion of sites for GCP violations. Controls (placebo) are appropriate. Independent replication is inherent in the two replicate trials.

Sub-criteria

controlsADEQUATE

power analysisINADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with adequate randomization, blinding, and prespecified analysis populations.

Evidence

paraphrase[Methods, Treatments and Randomization]

“The randomization schedule was generated with the use of RandAll NG software and was performed by means of interactive-response technology with a block size of six.”

direct quote[Methods, Treatments and Randomization]

“Trial staff members, patients, and investigators were unaware of trial-group assignments.”